Prostate cancer screening

“Facilitating Shared Decision Making About Prostate Cancer Screening Among African American Men” According to the ACS Statistics of cancer incidence rates among US males for 2003-2007, prostate cancer occurs more commonly in African American men than in white males (ACS, 2011-2012). Therefore, it is not only essential, but also vital to increase knowledge on the subject matter, raise general awareness, and promote shared decision making about screening and testing procedures. The authors of this

Prostate Cancer Screening: An Analysis The paper Prostate Cancer Screening is written as an analysis of the controversy on the use of screening for prostate cancer. The paper itself is written between doctors Elie Mulhem, Nikolaus Fulbright, and Norah Duncan. The analysis, while likely directed to those in the medical field, is tailored to be easily understood by laypeople. While the paper itself is a somewhat brief, surface level analysis of the situation, it does support the notion that prostate

Introduction This paper will focus on the economics of prostate cancer screening. The American Cancer Society states that cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death (10). According to the Centers for Disease Control and Prevention, cancer is the second leading cause of death. In 2002 alone, half a million Americans will die of this disease. Of this numerical figure, it is estimated that

brochure’s topic on Prostate Cancer Screening is consistent with Healthy People (HP) 2020 objectives on cancer. While the overall objective for all cancers is to “Reduce the number of new cancer cases, as well as the illness, disability, and death caused by cancer” (HP 2020, 2010), the specific objective for prostate cancer is to reduce prostate cancer death rate. The following information demonstrates the intent of the brochure to influence health behavior: a. Prostate cancer as the second leading

Introduction: Prostate cancer is the most common cancer in New Zealand and third most common cause of cancer death in the male population. Serum prostate-specific antigen (PSA) level is generally used as a screening test for asymptomatic patients. Patients with elevated serum PSA level and/or abnormal digital rectal examination undergo Transrectal ultrasound (TRUS) guided biopsy to detect early prostatic carcinoma. The histological grade of the cancer usually assessed using the Gleason grading

developing cancer, and > 10 ng/ml is a > 50% risk of cancer. However, some men with normal PSA levels still have prostate cancer, while other men with high PSA levels do not. PSA levels increase with age often due to a higher prevalence of benign prostate hypertrophy (BPH). Therefore, no PSA cutoff can accurately guarantee that a man does not have prostate cancer. PSA blood levels are used for several different purposes such as to diagnose prostate cancer, evaluate treatment of prostate cancer, and to

Interest Prostate cancer being a huge cause of mortality and medical expense in men age forty and above has only recently become a topic of general conversation to men in America (Plowden, 2009). African-American men are affected by prostate cancer at a disproportional level than all other men. They are diagnosed up to 65% more frequently and the mortality rate is twice that of Caucasian counterparts (Emerson, 2009). The African-American male is also less likely to take advantage of free prostate cancer

Prostate cancer is the second most common cancer and it is the second leading cause of cancer death in American men according to the American Cancer Society(ACS) ( 2016). Older age is the strongest risk factor for the development of prostate cancer. Approximately 1 in 7 men will be diagnosed with prostate cancer during his lifetime (ACS, 2016). There are more than 2.9 million prostate cancer survivors in the United States (ACS, 2016). The risk of dying from prostate cancer is 2.9 percent, with seventy

normal lifestyle. One of the several ailments that impedes typical human functioning is prostate cancer. The community of experts and professionals who have dedicated their lives to this field of study are, at this time, engaged in a substantive yet divisive and strongly opinionated dispute regarding a test considered by some to aid in the detection of this cancer. This highly scrutinized test is known as the prostate-specific antigen test, more commonly referred to as the PSA test. In the United States

5.0 Laboratory Tests 5.1 Prostate Specific Antigen (PSA) Table 2: Summary of characteristics Prostatic Specific Antigen (PSA) Characteristic Data Comments Classification PSA is a glycoprotein produced by the prostate epithelial cells Cancer may elevate levels both from increased production and because tissue barriers between the gland lumen and vascular bed are disrupted. PSA Levels PSA has a half-life of 2.2 days and elevated levels vary in recovery depending on the cause of the elevation PSA elevation